

# ANZGOG Preceptorship in Endometrial Cancer 2022

## Virtual 2-Day Education Event | Program



The Preceptorship in Endometrial Cancer is supported by **GSK**

**DAY 1 – Friday, 2 Dec | 12pm – 5.30pm AEDT**    **Day 2 – Saturday, 3 Dec | 10am – 12pm AEDT**

<b>Preceptors</b>	10 mins	<b>WELCOME</b> – <i>Michelle Wilson, Emma Allanson, Lawrence Kasherman</i>
<b>Path/Scientists</b> Michelle Alizart Rohan Laurie Pamela Pollock Dongli Liu	<b>12.10PM</b> (55 minutes)	<b>BASIC HISTOPATHOLOGY &amp; MOLECULAR PROFILING</b>  <b>Questions:</b> <ol style="list-style-type: none"> <li>How are endometrial carcinomas graded utilising the Figo grading system – how does histology impact prognosis and how reliable is this (eg. Stage 3)? How does traditional grading/typing correlate with molecular subtyping? - <i>Marilyn Boo</i></li> <li>What are the benefits and pitfalls of assessing p53 status by IHC in endometrial cancers? Approximately, what proportion of poor prognosis CNH tumours show a p53wildtype stainingpattern? - <i>Nisha Jagasia</i></li> </ol> <p style="text-align: center;"><b>5min Q&amp;A</b></p> <ol style="list-style-type: none"> <li>What are the benefits and pitfalls of IHC to detect retained expression of MMR protein expression in endometrial cancers? Can MSI (microsatellite instability) testing offer any additional information? - <i>Monica McGauran</i></li> <li>In what circumstances would <i>POLE</i> testing be requested for a patient, given the test is costly and time consuming? - <i>Paul Viray</i></li> </ol> <p style="text-align: center;"><b>10min PANEL DISCUSSION</b></p>
<b>GO</b> Nicole Krzys Mike Burling Cecile Bergzoll Nimithri Cabraal Orla McNally Alison Brand	<b>1.05PM</b> (80 minutes)	<b>SURGERY</b>  <b>Questions:</b> <ol style="list-style-type: none"> <li>What is the evidence that surgical approach affects outcomes for endometrial cancer patients? - <i>Monica McGauran</i></li> <li>What is the evidence of benefit of nodal staging in endometrial cancer? Is SLN dissection equivalent to full node dissection? - <i>Jason Phung</i></li> </ol> <p style="text-align: center;"><b>5min Q&amp;A</b></p> <ol style="list-style-type: none"> <li>How does histology and how might molecular profiling impact the extent of the operation performed? - <i>Marta Preston</i></li> <li>Who is eligible for fertility preserving surgery and what are the management options for these women? - <i>Charmian Eng</i></li> </ol> <p style="text-align: center;"><b>5min Q&amp;A</b></p> <ol style="list-style-type: none"> <li>Is there a role for interval debulking surgery after neoadjuvant chemotherapy for advanced endometrial cancer? Which patients will benefit and how? - <i>Georgie Mitchell</i></li> <li>How does BMI impact management and outcomes for women with endometrial cancer and how do you optimize care above BMI 40? - <i>Harrison Odgers</i></li> </ol> <p style="text-align: center;"><b>10min PANEL DISCUSSION</b></p>
<b>2.25 – 2.30pm</b>	<b>5min</b>	<b>BREAK</b>

<p><b>RO</b> Karen Lim Tiffany Daly Viet Do Jennifer Chard Ming-Yin Lin</p> <p><b>MO:</b> Mahesh Iddawela Kathrine Francis Yoland Antill (Mentor only) Sally Baron-Hay Felicia Roncolato Michelle Harrison Kate Webber Philip Beale (Mentor Only) Connie Diakos</p>	<p><b>2.30pm</b> (70 minutes)</p> <p><b>3.40PM</b> (55 minutes)</p> <p><b>4.35pm</b> (45 minutes)</p>	<p><b>ADJUVANT TREATMENT</b></p> <p><b><u>Radiation Treatment</u></b></p> <p><b>Questions:</b></p> <ol style="list-style-type: none"> <li>1. How has the technical delivery of external beam RT and brachytherapy for endometrial cancer evolved? - <i>Peter Nguyen</i></li> <li>2. When should we use brachytherapy vs external beam (or both)? - <i>Sylvie Chan</i> <b>5min Q&amp;A</b></li> <li>3. How may molecular profiling influence the use of adjuvant external beam RT or brachytherapy in a modern GYN Onc unit? - <i>Eric Fong</i></li> <li>4. What is the role of radiotherapy in Inoperable endometrial Cancer – this can be divided according to stage, and fitness for surgery. - <i>Krystal Tran</i> <b>5min Q&amp;A</b></li> <li>5. What short and long-term toxicities are associated with radiotherapy in endometrial cancer treatment? - <i>Cheryl Yim</i> <b>10min PANEL DISCUSSION</b></li> </ol> <p><b><u>Chemotherapy</u></b></p> <p><b>Questions:</b></p> <ol style="list-style-type: none"> <li>1. Which patients benefit from adjuvant chemotherapy? Is there a role for neo-adjuvant chemotherapy? - <i>Cassie Turner</i></li> <li>2. What is the optimal regimen for adjuvant chemotherapy? What is the optimal scheduling when both adjuvant chemotherapy and radiotherapy are given? What factors may influence scheduling? - <i>Hui-Ling Yeoh</i> <b>5min Q&amp;A</b></li> <li>3. What is the role for adjuvant chemotherapy in rare histological subtypes: serous, carcinosarcoma, clear cell carcinoma? - <i>Nadia Hitchen</i></li> <li>4. How might molecular profiling impact your systemic therapy recommendations, now and in the future? - <i>Paul Viray</i> <b>10min PANEL DISCUSSION</b></li> </ol> <p><b><u>Survivorship</u></b></p> <p><b>Questions:</b></p> <ol style="list-style-type: none"> <li>1. What surveillance should women with endometrial cancer undergo who have been treated with curative intent? - <i>Georgie Mitchell</i></li> <li>2. What survivorship issues affect women diagnosed with endometrial cancer? - <i>Thi Thuy Duong Pham</i> <b>5min Q&amp;A</b></li> <li>3. When is germline testing or genetic referral indicated? - <i>Nicole Leather</i> <b>10min PANEL DISCUSSION</b></li> </ol>
<p><b>5.20pm – 5.30pm</b></p>		<p><b>CLOSING</b> - <i>Michelle Wilson, Emma Allanson, Lawrence Kasherman</i></p>

DAY 2 – SATURDAY. 10.00AM – 12.00PM AEDT		
10.00am – 10.05am	(5mins)	<b>WELCOME</b> – <i>Michelle Wilson, Emma Allanson, Lawrence Kasherman</i>
10.05am - 10.25am	(20 minutes)	<b>How to get involved with ANZGOG clinical trials – mentoring new researchers</b> - <i>John Andrews</i>  <p style="text-align: center;"><b>5 min Q&amp;A</b></p>
10.25AM – 12.00PM	(85 Minutes)	<b>ADVANCED OR RECURRENT DISEASE</b>  <b>LOCAL THERAPY</b>  <b>Questions:</b> <ol style="list-style-type: none"> <li>1. What is the role of surgery in recurrent endometrial cancer? - <i>Nicla Liu</i></li> <li>2. What is the role of radiotherapy in recurrent endometrial cancer? how would you select patients appropriately for salvage radiotherapy? - <i>Annie McKean</i></li> </ol> <p style="text-align: center;"><b>10min PANEL DISCUSSION</b></p> <b>SYSTEMIC THERAPY</b>  <b>Questions:</b> <ol style="list-style-type: none"> <li>1. For patients with metastatic endometrial cancer, what are the minimal and optimal pathological and molecular markers needed to guide treatment decisions for advanced/recurrent disease? - <i>Elizabeth Driscoll</i></li> <li>2. What is the role of 1<sup>st</sup> and 2<sup>nd</sup> line chemotherapy in metastatic endometrial cancer? - <i>Jordan Cohen</i> <b>5min Q&amp;A</b></li> <li>3. What is the role of endocrine therapy in metastatic endometrial cancer? Should endocrine therapy be 1<sup>st</sup> line for patients with ER / PR + ve disease? - <i>Nadia Hitchen</i></li> <li>4. What is the role of immunotherapy in metastatic endometrial cancer? Discuss IO and IO combinations. - <i>Alina Mahmood</i> <b>5min Q&amp;A</b></li> <li>5. How do we manage HER2 amplified endometrial cancers? - <i>Jordan Cohen (5 min)</i></li> </ol> <p style="text-align: center;"><b>15min PANEL DISCUSSION</b></p>
12.00pm – 12.05pm		<b>CLOSING REMARKS</b> – <i>Michelle Wilson, Emma Allanson, Lawrence Kasherman</i>